TARGET IMAGING DIAGNOSIS OF HUMAN BRAIN GLIOMA - CLINICAL ANALYSIS OF40 CASES

Objective. To establish a method for localization and qualitative diag nosis of glioma. Methods. The monoclonal antibody SZ-39 against human glioma was labelled with I-131 and injected intravenously into 40 pati ents with intracranial occupying lesions proved by X-CT. 72 hours afte r I-131-McAb-SZ39 administration, cranial bone nuclide-imaging agent T c-99m-MDP was injected intravenously, and the patients were examined b y SPECT scan with dual nuclide double channel tomography and special s oftware. On radio-immune-image, the immunocomplex formed by specific c onjugation of I-131-McAb-SZ39 with target tissue was red, while the cr anial bone incorporated with Tc-99m-MDP was green. The location of the immunocomplex area could be identified by the superimposition of the images. Results. 21 patients with positive targeting diagnosis of glio ma showed the accuracy rate checked by SPECT was 81%(17/21) and by X-C T 48% (10/21). Seven patients with negative targeting diagnosis showed the accuracy rate checked by SPECT was 86%(6/7) and by X-CT 14%(1/7). Pathologically, the sensitivity of targeting SPECT to glioma was 94.5 %(17/18) and that of X-CT 55%(10/18). Conclusions. Targeting SPECT exa mination could be used for localization and qualitative diagnosis of g lioma and make up the inadequacy of X-CT in the qualitative diagnosis of atypical incipient and recurrent glioma, meningioma, metastatic car cinoma, and inflammatory lesions of brain.